Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy

• Yasutaka Fukuda,
• Marito Araki,
• Kouji Yamamoto,
• Soji Morishita,
• Tadaaki Inano,
• Kyohei Misawa,
• Tomonori Ochiai,
• Yoko Edahiro,
• Misa Imai,
• Hajime Yasuda,
• Akihiko Gotoh,
• Akimichi Ohsaka,
• Norio Komatsu

Affiliations

Yasutaka Fukuda

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo

Marito Araki

Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo

Kouji Yamamoto

Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka;Department of Biostatistics, Yokohama City University School of Medicine, Kanagawa

Soji Morishita

Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo

Tadaaki Inano

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo

Kyohei Misawa

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo

Tomonori Ochiai

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo

Yoko Edahiro

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo

Misa Imai

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo;Leading Center for the Development and Research of Cancer Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

Hajime Yasuda

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo

Akihiko Gotoh

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo

Akimichi Ohsaka

Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo

Norio Komatsu

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo